Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menstrual Bleeding Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

NCT03642210
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel 52 mg intrauterine system
Combination Product
Lead sponsor
Medicines360
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
29
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jun 10, 2026, 4:42 PM EDT
Terminated Not applicable Interventional Results available

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080
View directory record Official record
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jun 10, 2026, 4:42 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NCT05538689
View directory record Official record
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Orange, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
View directory record Official record
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
View directory record Official record
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jun 10, 2026, 4:42 PM EDT
Not yet recruiting Phase 2 Interventional

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

NCT07575308
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Interventions
ALN-6400
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957
View directory record Official record
Conditions
Venous Thromboembolism, Menstruation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 10, 2026, 4:42 PM EDT
Terminated No phase listed Observational

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

NCT05685199
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 40 Years · Female only
Enrollment
15 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070899
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
116
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

NCT06136104
View directory record Official record
Conditions
Healthy, Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions
Mixhers HERTIME, Placebo
Dietary Supplement
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of XP12B in Women With Menorrhagia

NCT00401193
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Jun 10, 2026, 4:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation

NCT02584088
View directory record Official record
Conditions
Menorrhagia
Interventions
Ultrasound
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jun 10, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

NCT05916469
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 10, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

NCT05922657
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions
Cerene
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 4:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

NCT00775190
View directory record Official record
Conditions
Contraception
Interventions
ortho tricyclen, Trinessa
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jun 10, 2026, 4:42 PM EDT
Withdrawn Phase 2 Interventional

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

NCT02794467
View directory record Official record
Conditions
Adenomyosis
Interventions
Epelsiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jun 10, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms

NCT07084714
View directory record Official record
Conditions
Premenstrual Syndrome, Menstrual Cycle, Menstrual Distress (Dysmenorrhea), Menstrual Bleeding, Heavy
Interventions
Moderate Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 10, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Sparrow Link, Sparrow Link (Sham)
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 10, 2026, 4:42 PM EDT
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jun 10, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jun 10, 2026, 4:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function

NCT00128726
View directory record Official record
Conditions
Menstrual Cycle, Healthy
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Jun 10, 2026, 4:42 PM EDT